“we have been commenting that we expect 50% of our growth to come from movement into the earlier stages of disease in oncology, as we look forward to ultimately get to a global percent with it being about 25% of our total revenues.”

In context

“t know that we are ever going to be done with that field in the near-term, so we are still very committed to do more. Rob Davis: Great. Thank you, Chris. Next question please, Julie. Operator: Thank you. Our next question comes from Mara Goldstein with Mizuho. Your line is open. Mara Goldstein: Great. Thanks so much for taking the question. I am curious the discussion around KEYTRUDA and migrating components of the revenue to earlier lines of therapy. Relative to when you first made statements about where you expect it to be from a percentage, do you think you are ahead of that at this point in time or on-track to where you originally thought you would be today. Rob Davis: Yeah. The short answer, Mara, is we are ahead of our -- of where we thought we would be. And just to remind everyone, we have been commenting that we expect 50% of our growth to come from movement into the earlier stages of disease in oncology, as we look forward to ultimately get to a global percent with it being about 25% of our total revenues. But I can tell you as where we sit here today, we are tracking ahead of where we expected we would be. And obviously not surprising when you see just a phenomenal results from KEYNOTE-671, what that’s going to mean in the perioperative space for people in early-stage lung cancer building on 091, the continued strength we are seeing across adjuvant and RCC and melanoma, we are up now to eight approvals in this space. So we are in a very good position. But I may about ask Caroline if she has anything she would like to add. Caroline Litchfield: The only thing I’d add, Rob, is to your point, we have made tremendous progress. We think this year we will have 20% of our KEYTRUDA business coming from the earlier stage cancer setting. And as we move forward given the tremendous state we have had a”